CLINICAL EFFICACY OF MOMETASONE FUROATE INHALATION
THERAPY IN ADULTS WITH POST-UPPER RESPIRATORY TRACT
INFECTION COUGH
SHANSHAN FENG1, GUOWEN ZHAN1, XIAOYA JING1, YANYAN CHEN2, YOUXIONG
YANG1*, HONGLI WANG1
1Ningbo Yinzhou No. 2 Hospital, ENT Department, Ningbo, Zhejiang 315100, China
2Ningbo Medical Treatment Center Lihuili Hospital Ningbo, Zhejiang 315100, China
*corresponding author: fkrt89@163.com
Download Full Article

Abstract:
This study was designed to explore the curative effect of mometasone furoate inhalation therapy on adult patients with airway
hyper-responsiveness (AHR) cough after having upper respiratory tract infection (URI). There were selected 56 patients who
were diagnosed with AHR cough (still having dry cough after treatment of URI). They were randomly divided into treatment
group and control group. Through chest radiography and nose endoscopy, the patients with chronic lung disease or perennial
rhinitis were excluded. Among the included patients, the treatment group was treated with mometasone furoate inhalation
therapy and oral administration of loratadine, while the control group was only treated with loratadine. Follow-up checkups
were performed respectively after one-week and two-week treatment. Visual analogue scale (VAS) was used to evaluate the
cough degree and cough duration of the patients. In the experimental group, cough duration was 11.60 ± 4.30 days; in the
control group, it was 15.00 ± 4.85 days; the difference was statistically significant (p < 0.05). The VAS score of the
experimental group was significantly lower than that of the control group (p < 0.05). In the early phase of the disease, the
application of mometasone furoate inhalation therapy can shorten the duration of post-URI chronic cough and relieve AHR
symptoms.

Top